Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 444 participants.

Also called NCT05391893

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 444 participants (enrolled count) (from the registry)
Sponsor
Corewell Health South (from the registry)
Registry
  • NCT NCT05391893
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05391893. Non-randomized; no masking; primary purpose treatment. Start 2020-06-19 (actual); primary completion 2023-04-01 (actual). Results posted on 2024-12-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
Intervention (Drug)
Oral
Intervention (Drug)
Intravenous drug
Lead sponsor
Corewell Health South (class: other)

Record details

Record id
cardio:ct-nct05391893
Content hash
71fa76a41b92f91e95c3e30ce4c86a313bb24141ee61b29fd5d921e60a15172a